Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2020-06-24 Director's Dealing
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
关于部分董事、监事及高级管理人员减持股份的预披露公告
Director's Dealing Classification · 100% confidence The document is a pre-disclosure announcement regarding the planned reduction of shareholdings by certain directors, supervisors, and senior management personnel of the company. It details the shareholders involved, their shareholdings, the planned reduction quantities, reasons for reduction, and compliance with relevant laws and regulations. There is no financial data, earnings information, or report publication mentioned. The content fits the definition of Director's Dealing, which involves reporting personal share transactions by company directors and executives (insider trades). The document length is short and focused solely on share reduction plans by insiders, confirming it is not a full financial report or announcement of a report publication. Therefore, the correct classification is Director's Dealing (DIRS).
2020-06-24 Chinese
公开发行可转换公司债券预案（修订稿）
Capital/Financing Update Classification · 95% confidence The document is titled "公开发行可转换公司债券预案（修订稿）" which translates to "Public Offering Convertible Corporate Bonds Proposal (Revised Draft)". It contains detailed information about the issuance of convertible bonds, including terms of issuance, bond features, conversion price adjustments, redemption and repurchase clauses, rights and obligations of bondholders, and the use of proceeds. It also includes extensive financial data such as consolidated and parent company balance sheets and income statements for multiple years and quarters, indicating substantive financial information is present. The document is not a simple announcement or a brief summary but a comprehensive proposal related to capital raising through convertible bonds. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document length (15,000 characters) and detailed financial data confirm it is not a mere announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2020-06-22 Chinese
关于调整2019年股票期权激励计划及相关文件中第二个行权期及第三个行权期个人层面绩效考核要求的公告
Board/Management Information Classification · 95% confidence The document is an announcement from a company regarding adjustments to its 2019 stock option incentive plan, specifically changes to the performance assessment requirements for the second and third exercise periods. It details board and supervisory committee meetings, independent director opinions, legal opinions, and financial advisor opinions related to the adjustment. The document does not contain financial statements or comprehensive financial data but rather focuses on governance and management decisions about stock option plans. It is not a full annual or interim report, earnings release, or audit report. It is also not a proxy solicitation or voting results announcement. The content fits best under Board/Management Information (MANG) as it announces changes in management incentive plans and related governance matters. The document length is under 5,000 characters, but it is substantive and not merely a report publication announcement or certification. Therefore, the classification is MANG with high confidence.
2020-06-22 Chinese
国浩律师（深圳）事务所关于公司调整2019年股票期权激励计划及相关文件中第二个行权期及第三个行权期个人层面绩效考核要求的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding adjustments to the 2019 stock option incentive plan of a company. It discusses the approval process, legal compliance, and specific changes to performance assessment criteria related to stock option exercise periods. There are no financial statements, earnings data, or investor presentations. The document is a legal opinion on a corporate governance matter related to stock option plans, which does not fit into financial reports or earnings releases. It is not a regulatory filing in the sense of general announcements but a formal legal opinion letter. Given the nature of the document, it best fits under Regulatory Filings (RNS) as it is a legal compliance document and does not match other more specific categories like Remuneration Information or Board/Management Information. The document length and content confirm it is not a brief announcement but a substantive legal opinion letter.
2020-06-22 Chinese
关于公开发行可转换公司债券预案的修订说明公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement regarding the revision of a convertible bond issuance plan by the company. It references board meetings and shareholder meetings approving the plan and its revisions, as well as compliance with regulatory requirements. The document is short (834 characters) and serves as a formal announcement of changes to a financing plan rather than the full detailed financing report itself. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2020-06-22 Chinese
关于召开2020年第三次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a detailed notice about the convening of the 2020 third extraordinary general meeting of shareholders for the company 健帆生物科技集团股份有限公司. It includes information about the meeting date, voting procedures (both in-person and online), agenda items to be discussed and voted on, registration details, and proxy forms. The content is focused on informing shareholders about the meeting logistics and agenda, rather than presenting financial results or management commentary. There is no financial data or report content, but rather a formal announcement and instructions related to a shareholders' meeting. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2020-06-22 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.